Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. is listed today as Scribe Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2021 | $100 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Scribe Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2021).
SEC Form D · Apr 2021
The industry group it chose in its notices: Other Technology.
SEC Form D · Apr 2021
That is all the official record says: Scribe Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Scribe Therapeutics, Inc. are on record.
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| AH Bio Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| AH Bio Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| AH Equity Partners Bio III, L.L.C. | Private equity | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| AH Equity Partners Bio II, L.L.C. | Private equity | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Jennifer A. Doudna | Person | not stated | not stated | Held Series A-1 preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, director (Form 3, 2026) | SEC Form 3 |
| OrbiMed Capital GP VIII LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, director (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 19 investors.
Largest shareholders today
Institutions holding Scribe Therapeutics Inc. shares, as of Sep 30, 2026.
- a16z Capital Management, L.L.C.$57 M16.28%
- Avoro Capital Advisors LLC$48 M13.73%
- Ra Capital Management, L.P.$33 M9.52%
- Orbimed Advisors LLC$25 M7.12%
- Perceptive Advisors LLC$17 M4.86%
- ARK Investment Management LLC$14 M4.16%
- Baker Bros. Advisors LP$13 M3.64%
- Price T Rowe Associates Inc /MD/$13 M3.62%
- BlackRock, Inc.$13 M3.59%
- Sanofi$9 M2.64%
- Vanguard Capital Management LLC$8 M2.15%
- Franklin Templeton Inc$7 M2.01%
- Farallon Capital Management, L.L.C.$7 M2.01%
- Adage Capital Partners GP, L.L.C.$7 M2.01%
- Geode Capital Management, LLC$5 M1.30%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Benjamin Oakes | Executive officer | Apr 2021 |
| Behzad Aghazadeh | Director | Apr 2021 |
| Benjamin Oakes | Director | Apr 2021 |
| Carl Gordon | Director | Apr 2021 |
| Vijay Pande | Director | Apr 2021 |
Went public since 2026. Its SEC number is that of a company listed on a stock exchange.